aurZ Antibody

What is Aurora A kinase and why are antibodies against it important in research?

Aurora A kinase (AURKA) is a serine/threonine kinase that plays crucial roles in mitotic progression, centrosome maturation, and spindle assembly. Antibodies against Aurora A are essential research tools for:

• Studying cell cycle regulation and mitotic abnormalities

• Investigating cancer mechanisms (Aurora A is frequently overexpressed in various malignancies)

• Examining protein localization through immunofluorescence techniques

• Quantifying Aurora A expression levels in different cell types and disease states

• Validating potential therapeutic targets in drug development pipelines

The clinical significance of Aurora A extends to its roles in tumor development and progression, making these antibodies valuable for both basic research and translational medicine applications.

How do I select the appropriate Aurora A antibody for my specific research application?

Selection of the appropriate Aurora A antibody should be based on:

• Application specificity: Different techniques require antibodies with different properties:

  • Western blotting: High specificity for denatured protein

  • Immunoprecipitation: Ability to recognize native protein

  • Immunohistochemistry: Compatibility with fixation methods

  • Flow cytometry: Recognition of cell surface or intracellular epitopes

• Species reactivity: Ensure the antibody recognizes Aurora A from your experimental species (human, mouse, rat, etc.)

• Clonality:

  • Monoclonal antibodies: Provide higher specificity but recognize a single epitope

  • Polyclonal antibodies: Recognize multiple epitopes but may have more cross-reactivity

• Validation data: Review published literature and manufacturer data showing validation in your specific application

• Recognized domain: Some antibodies recognize specific phosphorylation sites or functional domains, which may be important for your research questions

What are the most common methods for detecting and quantifying Aurora A using antibodies?

The most frequently employed methods include:

Cell-based ELISA methods, like those in the AurA Cell Based ELISA Kit, enable detection of Aurora A directly in cultured cells, allowing researchers to measure changes in expression under different experimental conditions .

What controls should I include when using Aurora A antibodies in my experiments?

Proper experimental controls are essential for reliable interpretation of antibody-based experiments:

• Positive control: Cell lines with known Aurora A expression (e.g., certain cancer cell lines with Aurora A overexpression)

• Negative control: Samples lacking Aurora A expression or knockdown/knockout models

• Isotype control: Non-specific antibody of the same isotype to control for non-specific binding

• Secondary antibody-only control: To assess background from secondary antibody

• Peptide competition: Pre-incubation of antibody with immunizing peptide to confirm specificity

• Normalization control: For quantitative applications, use housekeeping proteins (e.g., GAPDH, β-actin) or total protein stains

For cell-based assays, the AurA Cell Based ELISA Kit includes Anti-GAPDH antibody as an internal positive control for normalizing target values and Crystal Violet whole-cell staining to adjust for differences in cell density .

How do I troubleshoot non-specific binding or weak signals when using Aurora A antibodies?

When encountering issues with Aurora A antibody performance, consider these methodological solutions:

For non-specific binding:

• Increase blocking time/concentration (5% BSA or milk is typically effective)

• Optimize antibody dilution through titration experiments

• Include detergents (0.1-0.3% Tween-20) in wash buffers

• Pre-adsorb antibody with proteins from non-target species

• Consider using monoclonal antibodies for higher specificity

• Reduce primary antibody incubation time

For weak signals:

• Increase antibody concentration (but verify this doesn't increase background)

• Extend incubation time (overnight at 4°C often improves signal)

• Use signal amplification methods (e.g., biotin-streptavidin systems)

• Optimize antigen retrieval for fixed samples

• Ensure sample preparation preserves the epitope

• Verify your sample expresses detectable levels of Aurora A

For high background in immunofluorescence:

• Use confocal microscopy to reduce out-of-focus fluorescence

• Include an additional blocking step with serum from secondary antibody species

• Consider using directly conjugated primary antibodies to eliminate secondary antibody background

How can I validate the specificity of my Aurora A antibody?

Antibody validation is critical for ensuring experimental reliability. Multiple complementary approaches should be used:

• Genetic approaches:

  • siRNA/shRNA knockdown of Aurora A

  • CRISPR/Cas9 knockout models

  • Overexpression systems with tagged Aurora A

• Biochemical validation:

  • Western blot confirmation of expected molecular weight (Aurora A: ~46 kDa)

  • Mass spectrometry analysis of immunoprecipitated proteins

  • Peptide competition assays

• Orthogonal techniques:

  • Correlation between protein detection and mRNA levels

  • Multiple antibodies targeting different epitopes

  • Correlation with known biological functions (e.g., cell cycle patterns)

• Cross-reactivity assessment:

  • Testing against related proteins (e.g., Aurora B, Aurora C)

  • Testing in multiple species if claiming cross-reactivity

Document all validation steps meticulously for publication and reproducibility purposes.

How do Aurora A antibodies compare to antibodies against other Aurora kinases (Aurora B and C) in terms of specificity and cross-reactivity?

The Aurora kinase family shares significant sequence homology, which presents specificity challenges:

To minimize cross-reactivity:

• Use antibodies raised against the N-terminal region of Aurora A which has lower homology to other Aurora kinases

• Validate using overexpression and knockdown approaches

• Consider phospho-specific antibodies targeting Aurora A-specific phosphorylation sites

• Always confirm specificity in your experimental system

How can I optimize immunoprecipitation protocols for studying Aurora A binding partners and post-translational modifications?

Optimizing immunoprecipitation (IP) of Aurora A requires careful consideration of several factors:

Buffer optimization:

• For phosphorylation studies: Include phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride)

• For complex stability: Test different salt concentrations (150-300 mM NaCl)

• For nuclear complexes: Consider benzonase treatment to reduce DNA-mediated precipitation

• For membrane-associated complexes: Include 0.1-1% non-ionic detergents (e.g., NP-40, Triton X-100)

Antibody selection:

• Choose antibodies validated for IP applications

• Consider epitope location relative to protein interaction domains

• For post-translational modification studies, use antibodies that don't recognize modified regions that might be obscured by interactions

Crosslinking approaches:

• For transient interactions: Consider chemical crosslinking (e.g., DSP, formaldehyde)

• For antibody stabilization: Crosslink antibodies to beads to prevent antibody contamination in eluates

Elution strategies:

• Competitive elution with epitope peptides for gentler elution

• pH elution (glycine pH 2.5-3.0) with immediate neutralization for traditional approaches

• SDS elution for maximum recovery but potential denaturation of complexes

Analysis considerations:

• For mass spectrometry: Avoid keratin contamination and consider FASP (Filter-Aided Sample Preparation)

• For phosphorylation site mapping: Enrich phosphopeptides using TiO₂ or IMAC

• For validation: Perform reciprocal IPs of binding partners

What methodological approaches can improve the detection of specific Aurora A phosphorylation states using phospho-specific antibodies?

Phosphorylation state detection requires specialized approaches:

• Sample preparation optimization:

  • Rapid lysis in buffers containing phosphatase inhibitors (sodium orthovanadate, sodium fluoride, β-glycerophosphate)

  • Use of phosphatase inhibitor cocktails with multiple inhibitors targeting different phosphatase classes

  • Sample preparation at 4°C to minimize enzymatic activity

  • Consider synchronizing cells to enrich for specific cell cycle phases where Aurora A is active

• Antibody selection and validation:

  • Use antibodies specifically raised against phosphorylated peptides

  • Validate with phosphatase treatment controls

  • Consider testing multiple phospho-specific antibodies targeting different sites

  • Establish specificity using kinase-dead mutants or inhibitor treatments

• Technical considerations:

  • For Western blotting: Use PVDF membranes for phosphoproteins

  • Consider Phos-tag™ acrylamide gels for mobility shift assays

  • In microscopy: Use harsh extraction procedures to remove soluble proteins

  • For flow cytometry: Optimize fixation to preserve phosphoepitopes (avoid methanol fixation)

• Controls:

  • Lambda phosphatase-treated samples as negative controls

  • Okadaic acid or calyculin A treatment to increase phosphorylation

  • Aurora kinase inhibitor (e.g., MLN8237) treated samples

  • Phosphomimetic and phospho-dead mutants as reference points

How can I utilize Aurora A antibodies in investigating the role of Aurora A in non-mitotic functions and cancer pathways?

Recent research has revealed Aurora A functions beyond classical mitotic roles. Advanced research approaches include:

• Cell type-specific studies:

  • Compare antibody staining patterns between cancer and normal cells

  • Investigate post-mitotic cells (neurons, cardiomyocytes) for non-canonical functions

  • Use tissue microarrays with Aurora A antibodies to correlate expression with clinical outcomes

• Proximity-based interaction studies:

  • BioID or APEX2 fusion proteins to identify proximity interactions

  • PLA (Proximity Ligation Assay) using Aurora A antibodies paired with antibodies against suspected interactors

  • FRET-based approaches with fluorescently labeled antibodies

• Functional analysis:

  • Combine antibody detection with functional readouts (e.g., DNA damage markers)

  • Correlate Aurora A localization with cellular structures using super-resolution microscopy

  • Use live-cell imaging with tagged Aurora A to correlate with fixed-cell antibody staining

• Therapeutic development applications:

  • Use of Aurora A antibodies to validate target engagement of inhibitors

  • Biomarker development for patient stratification

  • Antibody-drug conjugate development targeting Aurora A in cancer cells

What are the key considerations when developing therapeutic antibodies targeting Aurora A or using Aurora A as a cancer biomarker?

Therapeutic antibody development targeting Aurora A presents unique challenges:

• Target accessibility issues:

  • Aurora A is predominantly intracellular, requiring specialized delivery approaches for therapeutic antibodies

  • Consider antibody formats with enhanced cell penetration (e.g., cell-penetrating peptides, nanocarriers)

  • Evaluate extracellular Aurora A as a potential target in certain cancer types

• Specificity and selectivity considerations:

  • Cross-reactivity with other Aurora kinases must be rigorously assessed

  • Off-target effects evaluation in healthy tissues

  • Potential for antibody-mediated immune responses

• Format selection:

  • Traditional IgG versus alternative formats (Nanobodies, scFvs)

  • Evaluation of smaller fragments for better tissue penetration

  • Consideration of bispecific formats to enhance tumor targeting

• Biomarker development approach:

  • Standardization of immunohistochemical protocols for clinical use

  • Quantitative assessment methods development

  • Correlation with treatment response and survival outcomes

  • Inclusion in multiplexed biomarker panels

• Delivery strategies:

  • Antibody-drug conjugates targeting Aurora A

  • Nanoparticle-based delivery systems

  • Cell-penetrating peptide conjugation strategies

Recent approaches have shown that novel antibody formats such as NANOBODY® compounds have advantages in terms of reduced immunogenicity and injection site reactions compared to traditional IgG therapeutics, which could be relevant for Aurora A-targeted therapies .

How do different fixation and permeabilization methods affect Aurora A epitope preservation for immunostaining?

The choice of fixation and permeabilization methods significantly impacts Aurora A detection:

Recommendations:

• For centrosome/spindle pole localization: Methanol fixation often provides optimal results

• For nuclear/cytoplasmic Aurora A: Paraformaldehyde followed by Triton X-100 permeabilization

• Always validate antibody performance with different fixation methods for your specific application

• Consider combining methods (e.g., brief paraformaldehyde followed by methanol)

What are the advantages and limitations of using antibodies versus genetic reporters (GFP-Aurora A) for studying Aurora A dynamics?

Both approaches have distinct advantages for studying Aurora A:

Antibody-based detection:

• Advantages:

  • Detects endogenous protein at physiological levels

  • Can target specific post-translational modifications

  • No need for genetic manipulation of cells

  • Can be used in clinical samples and tissues

  • Multiple epitopes can be targeted simultaneously

• Limitations:

  • Limited to fixed cells for most applications

  • Potential cross-reactivity issues

  • Batch-to-batch variability

  • Cannot track real-time dynamics

  • Epitope masking in protein complexes

Genetic reporters (GFP-Aurora A):

• Advantages:

  • Live-cell imaging capability

  • Real-time kinetics and dynamics

  • Can track individual molecules in some approaches

  • Consistent labeling across experiments

  • Allows FRAP and other dynamic studies

• Limitations:

  • Potential artifacts from overexpression

  • Tag may interfere with protein function

  • Requires genetic manipulation

  • Not suitable for clinical samples

  • May not represent all endogenous pools of the protein

Recommended combined approaches:

• Validate GFP-tagged constructs with antibody staining

• Use CRISPR knock-in of small tags for endogenous labeling

• Correlate live-cell dynamics with fixed-cell antibody staining

• Use antibodies for clinical correlations and GFP-fusion for mechanism studies

How can mass spectrometry complement antibody-based approaches for Aurora A research?

Mass spectrometry provides complementary data to antibody-based detection:

• Identification of novel post-translational modifications:

  • Unbiased discovery of phosphorylation, acetylation, ubiquitination sites

  • Quantitative analysis of modification stoichiometry

  • Detection of modifications for which antibodies don't exist

• Protein interaction analysis:

  • Identification of Aurora A binding partners after immunoprecipitation

  • Quantitative analysis of dynamic interactions during cell cycle

  • Cross-linking mass spectrometry (XL-MS) to map interaction interfaces

• Validation of antibody specificity:

  • Confirming the identity of immunoprecipitated proteins

  • Characterizing proteins detected in Western blot bands

  • Assessing off-target binding of antibodies

• Targeted quantification approaches:

  • Selected/Multiple Reaction Monitoring (SRM/MRM) for absolute quantification

  • Parallel Reaction Monitoring (PRM) for sensitive detection

  • AQUA peptides for standardization across samples

• Integrated workflow example:

  • Immunoprecipitate Aurora A using validated antibodies

  • Analyze by mass spectrometry to identify interactors and modifications

  • Develop targeted assays for key modifications

  • Validate findings using phospho-specific antibodies

This combined approach leverages the sensitivity and specificity of antibodies with the unbiased and comprehensive nature of mass spectrometry.

What considerations are important when using Aurora A antibodies across different model organisms?

Cross-species application of Aurora A antibodies requires careful consideration:

• Epitope conservation assessment:

  • Perform sequence alignment of Aurora A across target species

  • Focus on antibodies targeting highly conserved regions for cross-species applications

  • Be particularly careful with phospho-specific antibodies as phosphorylation sites may not be conserved

• Species-specific validation approaches:

  • Test antibody in knockout/knockdown models for each species

  • Verify correct molecular weight, which may vary between species

  • Confirm expected localization pattern (e.g., centrosomal in most species)

• Species-specific optimization considerations:

  • Adjust antibody concentration for each species

  • Modify blocking conditions (e.g., use serum from the same species as secondary antibody)

  • Optimize fixation protocols, which may differ between species

• Cross-reactivity concerns:

  • The AurA Cell Based ELISA Kit notes reactivity with human, mouse, and rat samples

  • Higher conservation within mammals compared to more distant organisms

  • Aurora kinase homologs in lower organisms (e.g., Ipl1 in yeast) may not be recognized

• Comparative studies approach:

  • Use multiple antibodies targeting different epitopes

  • Include species-specific positive controls

  • Consider generating species-specific antibodies for critical experiments

How are advanced microscopy techniques enhancing the use of Aurora A antibodies in research?

Cutting-edge microscopy approaches are revolutionizing Aurora A research:

• Super-resolution microscopy:

  • STORM/PALM enables localization of Aurora A with ~20nm precision

  • SIM provides detailed visualization of Aurora A at centrosomes and microtubules

  • Expansion microscopy physically enlarges samples for enhanced resolution with standard antibodies

• Live-cell approaches with antibody fragments:

  • Nanobodies or scFvs against Aurora A for live-cell imaging

  • SNAP/HALO-tag systems combined with labeled antibodies

  • Single-particle tracking of labeled antibody fragments

• Correlative light and electron microscopy (CLEM):

  • Antibody detection at light microscopy level followed by EM ultrastructure

  • Immunogold labeling of Aurora A for TEM

  • Precise localization within centrosome ultrastructure

• Multiplexed imaging approaches:

  • Cyclic immunofluorescence for detecting multiple targets sequentially

  • Mass cytometry (CyTOF) with metal-labeled antibodies

  • Multiplexed ion beam imaging (MIBI) for highly multiplexed tissue analysis

• Functional readouts:

  • FRET sensors combined with antibodies for activity status

  • Optogenetic approaches to modulate Aurora A while monitoring via antibodies

  • Integration with live-cell reporters of cell cycle progression

What are the challenges and solutions for studying Aurora A in clinical samples using antibodies?

Clinical sample analysis presents unique challenges:

• Pre-analytical variables:

  • Fixation timing affects phosphoepitope preservation (shorter time to fixation preserves phosphorylation)

  • Fixative choice (10% neutral buffered formalin standard in clinical settings)

  • Storage conditions of paraffin blocks or frozen samples

  • Antigen retrieval optimization critical for FFPE tissues

• Standardization approaches:

  • Use of automated staining platforms for consistency

  • Inclusion of control tissues with known Aurora A expression levels

  • Quantitative image analysis rather than subjective scoring

  • Detailed documentation of protocols for reproducibility

• Validation for clinical use:

  • Selection of antibodies with published validation in clinical samples

  • Correlation with orthogonal measures (e.g., mRNA expression)

  • Comparison across multiple antibodies targeting different epitopes

  • Blinded assessment by multiple pathologists

• Innovative approaches:

  • Tissue microarrays for high-throughput analysis

  • Digital pathology with automated quantification

  • Multiplexed immunofluorescence for context (co-expression with other markers)

  • Single-cell analysis from disaggregated clinical samples

• Recommended workflow:

  • Validate antibodies in cell lines with manipulation of Aurora A levels

  • Test in a small cohort of well-characterized clinical samples

  • Establish scoring criteria and cutoffs for positivity

  • Implement rigorous quality control measures

How does the development of therapeutic antibodies targeting Aurora A differ from research-focused antibody development?

Therapeutic antibody development has distinct requirements from research antibodies:

• Target validation considerations:

  • Expression profiling across normal and disease tissues

  • Safety assessment based on normal tissue expression

  • Functional validation of Aurora A dependence in disease models

  • Careful assessment of on-target toxicity potential

• Format and engineering considerations:

  • IgG subclass selection based on desired effector functions

  • Fc engineering for optimal half-life and tissue penetration

  • Consideration of alternative formats (bispecifics, ADCs, etc.)

  • Sequence optimization for reduced immunogenicity

• Manufacturing and characterization requirements:

  • Stable cell line development for consistent production

  • Extensive characterization of critical quality attributes

  • Formulation development for stability

  • Scale-up considerations for clinical manufacturing

• Preclinical testing scope:

  • In vitro potency and mechanism of action studies

  • In vivo efficacy in relevant disease models

  • Comprehensive toxicology studies

  • Pharmacokinetic and biodistribution analyses

• Regulatory considerations:

  • Documentation requirements for IND submission

  • GMP manufacturing compliance

  • Clinical trial design considerations

  • Companion diagnostic development if needed

Recent innovations with nanobody technology show promising results with reduced immunogenicity profiles (as seen with ozoralizumab), which could be relevant for Aurora A-targeted therapeutics .

How are computational approaches enhancing antibody research and development for targets like Aurora A?

Computational methods are increasingly important in antibody research:

• Epitope prediction and antibody design:

  • Structural modeling of Aurora A to identify accessible epitopes

  • In silico prediction of immunogenic regions

  • Antibody structure prediction and optimization

  • Molecular dynamics simulations of antibody-antigen interactions

• High-content image analysis:

  • Automated quantification of immunofluorescence signals

  • Machine learning for pattern recognition in cellular localization

  • Correlation of Aurora A levels with phenotypic outcomes

  • Multi-parametric analysis across large datasets

• Systems biology integration:

  • Network analysis of Aurora A interactions

  • Integration of antibody-derived data with genomic datasets

  • Pathway modeling to predict intervention points

  • Patient stratification algorithms based on Aurora A and related biomarkers

• Therapeutic antibody optimization:

  • Computational humanization approaches

  • Immunogenicity prediction algorithms

  • Pharmacokinetic modeling based on antibody properties

  • Affinity maturation through in silico design

• Emerging approaches:

  • AI-driven epitope prediction for phospho-specific antibodies

  • Next-generation sequencing of antibody repertoires

  • Virtual screening of antibody libraries

  • Quantum computing applications for complex antibody-antigen interactions

The integration of computational approaches with traditional wet-lab experimentation accelerates both basic research and therapeutic development for targets like Aurora A.